U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07303218) titled 'The HER Project: HRD in EGFR-mutated NSCLC' on Dec. 11.
Brief Summary: This observational retrospective-prospective study aims to evaluate the prevalence of homologous recombination deficiency (HRD) in metastatic EGFR mutated NSCLC and to assess its correlation with clinical and molecular features. Based on the hypothesis that HRD identifies a distinct EGFRm subgroup with prognostic value and a potential sensitivity to PARP inhibitor-based strategies, translational analysis will be performed with multiple pre-clinical models, ranging from human cancer cells to murine models.
Study Start Date: Dec. 01
Study Type: OBSERVATIONAL
Con...